Compare CSIQ & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSIQ | FLGT |
|---|---|---|
| Founded | 2001 | 2011 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 746.1M | 697.3M |
| IPO Year | 2006 | 2016 |
| Metric | CSIQ | FLGT |
|---|---|---|
| Price | $27.06 | $29.54 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 9 | 3 |
| Target Price | $17.63 | ★ $28.33 |
| AVG Volume (30 Days) | ★ 8.3M | 407.3K |
| Earning Date | 11-13-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,899,139,000.00 | $315,549,000.00 |
| Revenue This Year | N/A | $15.19 |
| Revenue Next Year | $24.59 | $10.58 |
| P/E Ratio | $112.81 | ★ N/A |
| Revenue Growth | N/A | ★ 13.61 |
| 52 Week Low | $6.57 | $14.57 |
| 52 Week High | $34.59 | $31.04 |
| Indicator | CSIQ | FLGT |
|---|---|---|
| Relative Strength Index (RSI) | 57.90 | 66.14 |
| Support Level | $20.27 | $28.65 |
| Resistance Level | $34.59 | $31.04 |
| Average True Range (ATR) | 3.53 | 1.13 |
| MACD | -0.57 | 0.09 |
| Stochastic Oscillator | 49.20 | 66.03 |
Canadian Solar Inc is a Canadian solar technology and renewable energy company. It is a manufacturer of solar photovoltaic modules, a provider of battery energy storage solutions, and a developer of utility-scale solar power and battery energy storage projects.. It operates through two business segments CSI Solar and Recurrent Energy segment. The CSI Solar segment focused on solar modules and battery energy storage manufacturing and products. Its Recurrent segment focused on utility-scale solar power and battery energy storage project development and operation. Key revenue is generated from CSI Solar segment.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.